-->

Franco CPA - Biomea Fusion CFO Officer

BMEA Stock  USD 1.57  0.09  5.42%   

CFO

Franco CPA is CFO Officer of Biomea Fusion
Age 44
Phone650 980 9099
Webhttps://biomeafusion.com

Biomea Fusion Management Efficiency

The company has return on total asset (ROA) of (0.7421) % which means that it has lost $0.7421 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.5681) %, meaning that it created substantial loss on money invested by shareholders. Biomea Fusion's management efficiency ratios could be used to measure how well Biomea Fusion manages its routine affairs as well as how well it operates its assets and liabilities.
Biomea Fusion currently holds 8.77 M in liabilities with Debt to Equity (D/E) ratio of 0.02, which may suggest the company is not taking enough advantage from borrowing. Biomea Fusion has a current ratio of 16.13, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Biomea Fusion's use of debt, we should always consider it together with its cash and equity.

Similar Executives

Found 1 records

CFO Age

Jotin MDIkena Oncology
45
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. The company was incorporated in 2017 and is headquartered in Redwood City, California. Biomea Fusion operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 72 people. Biomea Fusion (BMEA) is traded on NASDAQ Exchange in USA. It is located in 1599 Industrial Road, San Carlos, CA, United States, 94070 and employs 79 people. Biomea Fusion is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Biomea Fusion Leadership Team

Elected by the shareholders, the Biomea Fusion's board of directors comprises two types of representatives: Biomea Fusion inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Biomea. The board's role is to monitor Biomea Fusion's management team and ensure that shareholders' interests are well served. Biomea Fusion's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Biomea Fusion's outside directors are responsible for providing unbiased perspectives on the board's policies.
Juan MD, Chief Officer
Caroline Dupont, Senior Contracts
Stephan MD, Chief Officer
Franco Valle, CFO Officer
Ravi Upasani, Executive Property
Ramses Erdtmann, President, CoFounder
Thomas Butler, Chairman CoFounder
Thorsten Kirschberg, Executive Chemistry
Franco CPA, CFO Officer
Alex Cacovean, Vice Sciences
Naomi Cretcher, Chief Officer
Heow Tan, Chief Officer
Michael Hitchcock, Interim Director
Caroline JD, Senior Contracts

Biomea Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Biomea Fusion a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Biomea Fusion offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Biomea Fusion's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biomea Fusion Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biomea Fusion Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biomea Fusion. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.
For information on how to trade Biomea Stock refer to our How to Trade Biomea Stock guide.
You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biomea Fusion. If investors know Biomea will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biomea Fusion listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Biomea Fusion is measured differently than its book value, which is the value of Biomea that is recorded on the company's balance sheet. Investors also form their own opinion of Biomea Fusion's value that differs from its market value or its book value, called intrinsic value, which is Biomea Fusion's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biomea Fusion's market value can be influenced by many factors that don't directly affect Biomea Fusion's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biomea Fusion's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biomea Fusion is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biomea Fusion's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.